Trending archive
Every article that has appeared in Trending stays here. Search by title, journal, author or PMID, and narrow by date.
1566 articles
October 202624
Exposure-Response Analyses of Ropeginterferon Alfa-2b in Essential Thrombocythemia.
This meta-analysis examined the population pharmacokinetics and pharmacodynamics of ropeginterferon alfa-2b in patients with essential thrombocythemia (ET).
A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers.
This Phase I multicenter study evaluated PF-07062119, an anti-GUCY2C/anti-CD3 bispecific antibody, in 79 patients with advanced gastrointestinal cancers.
Clinical Trial Protocol for LPS-Boost: Intensified [ 177 Lu]Lu-PSMA-617 Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with Low PSMA-Expressing Disease.
This multicenter, open-label phase 2 trial investigates an intensified treatment schedule of [177Lu]Lu-PSMA-617 for 45 patients with metastatic castration-resistant prostate cancer (mCRPC) and low PSMA expression.
Long-Term Safety and Efficacy of Dazukibart in Dermatomyositis: Combined Phase II Results From Double-Blind and Open-Label Extension Studies.
This study evaluated the long-term safety and efficacy of dazukibart, an antiinterferon β monoclonal antibody, in adults with moderate-to-severe dermatomyositis through a combined Phase II randomized controlled trial…
Tumor and Organ Dose Estimates from 177 Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial.
The RESIST-PC Phase 2 trial assessed dosimetry of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. A total of 48 patients were analyzed, receiving either 6.0 or 7.4 GBq per cycle.
A Phase 2, Open-Label, Randomized Controlled Trial Evaluating Safety and Efficacy of Dose-Intensified Versus Standard Dosing Regimens of [ 177 Lu]Lu-PSMA-597 in mCRPC (OPTIMAL-PSMA).
The OPTIMAL-PSMA study is a Phase 2, open-label, randomized controlled trial evaluating the safety and efficacy of a dose-intensified regimen of [177Lu]Lu-PSMA-597 versus standard dosing in 120 patients with metastatic…
Phase I Trial of GPC3-Targeted TCR Fusion Construct, CT0180, in Patients with Advanced Hepatocellular Carcinoma.
This Phase I open-label trial evaluated the safety and preliminary efficacy of CT0180, a GPC3-targeted TCR fusion construct, in patients with advanced hepatocellular carcinoma (HCC) who had progressed on standard…
Investigation of a Prostate Cancer Radiation Response Signature in the Breast Cancer SweBCG91RT Randomized Trial.
This randomized controlled trial evaluated the Prostate cancer Radiation Therapy Outcomes Score (PORTOS) in predicting radiotherapy benefit in 765 patients with early-stage breast cancer.
The Effectiveness of Incentives on Cancer Screening among Indigenous Populations: Systematic Review.
This systematic review assessed the effectiveness of various incentives on cancer screening participation among Indigenous populations.
First-in-Human, Open-label, Single-Arm Phase I Study of [211At] meta-Astatobenzylguanidine in Patients with Pheochromocytoma or Paraganglioma.
This first-in-human, open-label, single-arm Phase I study evaluated the safety and pharmacokinetics of 211At-meta-astatobenzylguanidine (211At-MABG) in 10 patients with unresectable or metastatic pheochromocytomas or…
How I treat thrombotic microangiopathy in the setting of triggers.
A patient presented with thrombotic microangiopathy during pregnancy, which complicated the diagnosis due to the potential trigger.
Long-term Follow-up of Third-generation Anti-CD30 CAR T-cell Therapy in Relapsed/Refractory CD30+ Lymphomas: A Single-Arm, Multicenter, Phase I/II Trial.
This single-arm, multicenter, phase I/II trial evaluated long-term outcomes of third-generation anti-CD30 CAR T-cell therapy in 44 patients with relapsed/refractory CD30+ lymphoma.
Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT).
The TRIDENT analysis, a post hoc study of the POSEIDON trial, utilized machine learning to identify patients with metastatic non-small cell lung cancer (NSCLC) who may benefit from adding tremelimumab to durvalumab and…
Molecular Profiling of Tisotumab Vedotin-Treated Patients Identifies Immune Pathways Associated with Clinical Activity.
This phase II multicenter trial evaluated the efficacy of tisotumab vedotin (TV) in patients with recurrent or metastatic cervical cancer (r/mCC).
Nonarmored GCC-Targeting CAR T-cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer.
This phase I clinical trial evaluated the safety and preliminary efficacy of nonarmored GCC-targeted CAR T-cell therapy in 24 heavily pretreated metastatic colorectal cancer patients.
Tumor-Infiltrating Lymphocytes as a Predictor of Adjuvant Avelumab Efficacy in Patients with High-risk Triple-Negative Breast Cancer.
This phase III randomized controlled trial investigated the prognostic and predictive value of tumor-infiltrating lymphocytes (TIL) in 466 patients with high-risk early triple-negative breast cancer (TNBC) receiving…
Durable efficacy and manageable long-term safety of lisocabtagene maraleucel for 3L+ FL: 3-year update from TRANSCEND FL.
The TRANSCEND FL study evaluated the long-term efficacy and safety of lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory follicular lymphoma (FL) after at least two prior therapies.
Perioperative Safety and Effectiveness of Laparoscopic Heller Myotomy in Elderly Patients: Systematic Review and Meta-Analysis.
This systematic review and meta-analysis evaluated the perioperative safety and effectiveness of laparoscopic Heller myotomy (LHM) in patients aged 65 years or older.
A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus.
This phase II randomized controlled trial evaluated the efficacy of bispecific antibodies lomvastomig and tobemstomig against nivolumab in 190 checkpoint inhibitor-naïve patients with advanced esophageal squamous cell…
Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.
This single-arm phase I trial evaluated the combination of avutometinib, abemaciclib, and fulvestrant in 16 patients with HR+/HER2- metastatic breast cancer who had previously progressed on CDK4/6 inhibitors.
Osimertinib plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.
The ORCHARD study was a phase II trial assessing the efficacy of osimertinib plus gefitinib in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) and EGFR C797X mutation after progression on…
Modified One Anastomosis Gastric Bypass (OAGB) Versus Duodenojejunostomy for Treatment of Superior Mesenteric Artery Syndrome: A Randomized Controlled Trial.
This randomized controlled trial compared modified one anastomosis gastric bypass (OAGB) to duodenojejunostomy in 20 patients with superior mesenteric artery syndrome.
Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG.
The PBTC-051 study evaluated the safety and preliminary efficacy of the CD40 agonist sotigalimab in 31 pediatric and young adult patients with recurrent CNS tumors and newly diagnosed DIPG.
The Duke CSF-Venous Fistula Confidence Score: Real-World Application on CT Myelography.
A case of a patient with spontaneous intracranial hypotension was evaluated using CT myelography to identify a suspected CSF-venous fistula (CVF).
Stay updated for free
Get the 3 most interesting publications in one specialty each week.
Weekly email. Unsubscribe anytime.
Want this personalized?
Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.
- Your specialties
- Your filters and thresholds
- Clinical Research + Case Reports, tuned separately
- Automatic weekly delivery
- Audio and text
Prefer listening? Personalized audio digests are available with Pro.